Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
Denmark
Herlev and Gentofte Hospital, Center for Cancer Research, Herlev Spain
Institut Catalá de Oncologia - Hospital Duran i Reynals., Barcelona Fundacion Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (FJD), Madrid Centro Integral Oncológico Clara Campal (CIOCC), Madrid Consorcio Hospital General Universitario de Valencia, Valencia